At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 627 enrolled
Drug / intervention
GW685698Xdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blind, Double Dummy, Placebo-Controlled, Parallel-Group, Multicenter Dose Ranging Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder Once Daily and Fluticasone Propionate Inhalation Powder 500mcg Twice Daily Compared With Placebo for 8 Weeks in Adolescent an
In Brief
A Phase 2 clinical trial evaluating GW685698X for Asthma. Completed, enrolled 627 participants across 154 sites in 16 countries.
Detailed Summary
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesAustralia, Bulgaria, Canada, Chile, Czechia, Estonia, France, Germany, Mexico, Netherlands, Peru, Poland, Russia, South Africa, Thailand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedJan 2008
Primary CompletionSep 2008
Study CompletionSep 2008
TodayJul 2026
First PostedJan 29, 2008
Enrollment StartDec 1, 2007
Primary CompletionSep 1, 2008
Study CompletionSep 20, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.4 years ago
Interventions
GW685698Xdrug
GW685698X